Oxford Medistress is commercialising a novel in vitro blood test device which aims to provide the first objective, quantitative measurement of stress.

TdeltaS is committed to developing science-based proprietary products that sit at the interface of food and pharmaceuticals - nutraceuticals - and offer real improvement in human physical and mental performance.

Velocys, previously Oxford Catalysts, produces speciality catalysts for the generation of clean fuels, from both conventional fossil fuels and renewable sources such as biomass.

Celleron is an oncology healthcare company that has developed biomarkers using epigenetic techniques that match drugs to responsive disease.

Oxbridge Pulsar Sources (OPS) is researching and developing novel radio transmitting antennas, based on new principles.

Robust, networked sensors for oilfield machinery, drilling and metering.

Oxford Nanopore Technologies is developing and commercialising a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins.

EKB Technology commercialises a revolutionary Bioprocessing Technology developed for the use of biological systems such as plant and animal cells and microorganisms to modify, produce or purify chemical intermediates.

Surface Therapeutics is a drug discovery and development company developing innovative new drugs to treat inflammatory epithelial diseases of the skin and lungs. Surface Therapeutics was acquired by Serentis Inc in September 2007.

G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.

Oxford Medical Diagnostics develops and supplies breath analysis technologies for rapid, accurate, and low-cost monitoring of diseases and metabolic functions.

Breath analysis.

Oxford Consultants for Social Inclusion (OCSI) helps local government identify deprived neighbourhoods, target resources, evaluate programme effectiveness and strengthen regeneration bids.

A biotherapeutics company, established to exploit the work in Viral Hepatitis undertaken at Imperial College, London and at Oxford University through the Wellcome Trust Centre for Human Genetics.

ReOx is a drug discovery company that is building on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Chemical genomics.

BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.

Oxford Risk is the market-leading provider of customer risk profilers. Their products reveal the level of risk customers are willing and able to take with their financial investments.

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. In 2021, Oxford Immunotec was acquired by PerkinElmer.